Cite
HARVARD Citation
Czarnogorski, M. et al. (2022). Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials. Journal of acquired immune deficiency syndromes. pp. 157-161. [Online].